294 related articles for article (PubMed ID: 19050385)
21. Cancer in HIV-infected persons from the Caribbean, Central and South America.
Fink VI; Shepherd BE; Cesar C; Krolewiecki A; Wehbe F; Cortés CP; Crabtree-Ramírez B; Padgett D; Shafaee M; Schechter M; Gotuzzo E; Bacon M; McGowan C; Cahn P; Masys D;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):467-73. PubMed ID: 21239992
[TBL] [Abstract][Full Text] [Related]
22. Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America.
Engels EA; Yanik EL; Wheeler W; Gill MJ; Shiels MS; Dubrow R; Althoff KN; Silverberg MJ; Brooks JT; Kitahata MM; Goedert JJ; Grover S; Mayor AM; Moore RD; Park LS; Rachlis A; Sigel K; Sterling TR; Thorne JE; Pfeiffer RM; ;
Clin Infect Dis; 2017 Aug; 65(4):636-643. PubMed ID: 29017269
[TBL] [Abstract][Full Text] [Related]
23. Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults.
Crum-Cianflone NF; Wang X; Ganesan A; Okulicz J; Weintrob A; Lalani T; Agan B
AIDS Res Hum Retroviruses; 2015 May; 31(5):514-8. PubMed ID: 25417712
[TBL] [Abstract][Full Text] [Related]
24. The Association of HIV Control and Immunosuppression With Risk of Non-AIDS-Defining Cancer Risk Among Patients on Antiretroviral Therapy.
Dickey BL; Yanik EL; Thompson Z; Burkholder G; Kitahata MM; Moore RD; Jacobson J; Mathews WC; Christopoulos KA; Fleming J; Napravnik S; Achenbach C; Coghill AE
J Acquir Immune Defic Syndr; 2024 Mar; 95(3):275-282. PubMed ID: 37977197
[TBL] [Abstract][Full Text] [Related]
25. Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.
Yang CH; Huang YF; Hsiao CF; Yeh YL; Liou HR; Hung CC; Yang SY
HIV Med; 2008 Aug; 9(7):535-43. PubMed ID: 18554309
[TBL] [Abstract][Full Text] [Related]
26. Epidemiological trends and therapeutic challenges of malignancies in adult HIV-1-infected patients receiving combination antiretroviral therapy in a tertiary hospital from Romania: An observational retrospective study.
Gheorghiță V; Conea IF; Radu AMC; Ștefan I; Mărdărescu M; Petrea S; Streinu-Cercel A
J Infect Public Health; 2019; 12(2):182-189. PubMed ID: 30344102
[TBL] [Abstract][Full Text] [Related]
27. Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use?
Crum-Cianflone NF; Grandits G; Echols S; Ganesan A; Landrum M; Weintrob A; Barthel R; Agan B;
J Acquir Immune Defic Syndr; 2010 Jul; 54(3):248-57. PubMed ID: 20658748
[TBL] [Abstract][Full Text] [Related]
28. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.
Althoff KN; Buchacz K; Hall HI; Zhang J; Hanna DB; Rebeiro P; Gange SJ; Moore RD; Kitahata MM; Gebo KA; Martin J; Justice AC; Horberg MA; Hogg RS; Sterling TR; Cescon A; Klein MB; Thorne JE; Crane HM; Mugavero MJ; Napravnik S; Kirk GD; Jacobson LP; Brooks JT;
Ann Intern Med; 2012 Sep; 157(5):325-35. PubMed ID: 22944874
[TBL] [Abstract][Full Text] [Related]
29. Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study.
Chammartin F; Lodi S; Logan R; Ryom L; Mocroft A; Kirk O; d'Arminio Monforte A; Reiss P; Phillips A; El-Sadr W; Hatleberg CI; Pradier C; Bonnet F; Law M; De Wit S; Sabin C; Lundgren JD; Bucher HC;
Ann Intern Med; 2021 Jun; 174(6):768-776. PubMed ID: 33721519
[TBL] [Abstract][Full Text] [Related]
30. Cancer risk in people infected with human immunodeficiency virus in the United States.
Engels EA; Biggar RJ; Hall HI; Cross H; Crutchfield A; Finch JL; Grigg R; Hylton T; Pawlish KS; McNeel TS; Goedert JJ
Int J Cancer; 2008 Jul; 123(1):187-94. PubMed ID: 18435450
[TBL] [Abstract][Full Text] [Related]
31. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
32. Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART.
Franzetti M; Adorni F; Parravicini C; Vergani B; Antinori S; Milazzo L; Galli M; Ridolfo AL
J Acquir Immune Defic Syndr; 2013 Apr; 62(4):414-20. PubMed ID: 23274934
[TBL] [Abstract][Full Text] [Related]
33. Trends in cancer diagnoses and survival among persons with AIDS in a high HIV prevalence urban area.
Castel AD; Young H; Akiwumi AM; Vargas A; Rogers K; West T; Levine PH
AIDS Care; 2015; 27(7):860-9. PubMed ID: 25714364
[TBL] [Abstract][Full Text] [Related]
34. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
35. Predictors of progression to AIDS after HIV infection diagnosis in the pre- and post-HAART eras in a Brazilian AIDS-free cohort.
Tancredi MV; Waldman EA
Trans R Soc Trop Med Hyg; 2014 Jul; 108(7):408-14. PubMed ID: 24836061
[TBL] [Abstract][Full Text] [Related]
36. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?
Pettit AC; Jenkins CA; Stinnette SE; Rebeiro PF; Blackwell RB; Raffanti SP; Shepherd BE; Sterling TR
J Acquir Immune Defic Syndr; 2011 Aug; 57(4):305-10. PubMed ID: 21423024
[TBL] [Abstract][Full Text] [Related]
37. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.
Yanik EL; Napravnik S; Cole SR; Achenbach CJ; Gopal S; Dittmer DP; Olshan AF; Kitahata MM; Mugavero MJ; Saag M; Moore RD; Mathews WC; Hunt P; Eron JJ
AIDS; 2014 Apr; 28(7):979-87. PubMed ID: 24681415
[TBL] [Abstract][Full Text] [Related]
38. HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts.
Castilho JL; Luz PM; Shepherd BE; Turner M; Ribeiro SR; Bebawy SS; Netto JS; McGowan CC; Veloso VG; Engels EA; Sterling TR; Grinsztejn B
Infect Agent Cancer; 2015; 10():4. PubMed ID: 25685180
[TBL] [Abstract][Full Text] [Related]
39. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.
Crum NF; Riffenburgh RH; Wegner S; Agan BK; Tasker SA; Spooner KM; Armstrong AW; Fraser S; Wallace MR;
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):194-200. PubMed ID: 16394852
[TBL] [Abstract][Full Text] [Related]
40. The Trends and Risk Factors of AIDS-Defining Cancers and Non-AIDS-Defining Cancers in Adults Living with and without HIV: A Narrative Review.
Mathoma A; Sartorius B; Mahomed S
J Cancer Epidemiol; 2024; 2024():7588928. PubMed ID: 38549952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
